Q1 Earnings Forecast for Beam Therapeutics Issued By Wedbush

Beam Therapeutics Inc. (NASDAQ:BEAM) – Investment analysts at Wedbush decreased their Q1 2025 EPS estimates for Beam Therapeutics in a report issued on Tuesday, February 25th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($1.21) per share for the quarter, down from their previous forecast of ($1.16). Wedbush has a “Outperform” rating and a $57.00 price target on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. Wedbush also issued estimates for Beam Therapeutics’ Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($1.18) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($4.81) EPS, FY2026 earnings at ($5.60) EPS, FY2027 earnings at ($5.42) EPS and FY2028 earnings at ($4.15) EPS.

Other equities analysts have also issued research reports about the company. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Beam Therapeutics in a research report on Friday. Cantor Fitzgerald raised Beam Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Wednesday, January 29th. Leerink Partners raised Beam Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $27.00 to $39.00 in a research report on Wednesday, November 6th. Sanford C. Bernstein raised Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 7th. Finally, Royal Bank of Canada lifted their price objective on Beam Therapeutics from $24.00 to $26.00 and gave the stock a “sector perform” rating in a report on Wednesday. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $50.90.

Beam Therapeutics Trading Down 2.8 %

Shares of Beam Therapeutics stock opened at $26.34 on Thursday. The firm has a market capitalization of $2.18 billion, a P/E ratio of -14.97 and a beta of 1.92. The business has a fifty day simple moving average of $27.23 and a two-hundred day simple moving average of $25.92. Beam Therapeutics has a 12 month low of $20.84 and a 12 month high of $45.05.

Beam Therapeutics (NASDAQ:BEAM) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.25) by $0.16. The business had revenue of $30.00 million for the quarter, compared to analysts’ expectations of $16.47 million. Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The firm’s revenue for the quarter was down 90.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.73 earnings per share.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Polar Asset Management Partners Inc. boosted its position in shares of Beam Therapeutics by 901.2% during the 4th quarter. Polar Asset Management Partners Inc. now owns 208,255 shares of the company’s stock worth $5,165,000 after acquiring an additional 187,455 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Beam Therapeutics during the 4th quarter worth about $43,000. Woodline Partners LP acquired a new position in shares of Beam Therapeutics during the 4th quarter worth about $6,997,000. Squarepoint Ops LLC acquired a new position in shares of Beam Therapeutics during the 4th quarter worth about $3,851,000. Finally, Twinbeech Capital LP boosted its position in shares of Beam Therapeutics by 119.3% during the 4th quarter. Twinbeech Capital LP now owns 127,664 shares of the company’s stock worth $3,166,000 after acquiring an additional 69,456 shares in the last quarter. 99.68% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Beam Therapeutics

In other news, CEO John M. Evans sold 30,000 shares of Beam Therapeutics stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $26.75, for a total value of $802,500.00. Following the completion of the sale, the chief executive officer now directly owns 908,659 shares of the company’s stock, valued at approximately $24,306,628.25. The trade was a 3.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Christine Bellon sold 1,241 shares of Beam Therapeutics stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total value of $30,627.88. Following the completion of the sale, the insider now directly owns 102,968 shares of the company’s stock, valued at $2,541,250.24. The trade was a 1.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 4.20% of the company’s stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.